Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Who will be eligible? An investigation of the dementia population eligible for cholinesterase treatment following the change in NICE guidance.

Authors
Type
Published Article
Journal
International journal of geriatric psychiatry
Publication Date
Volume
25
Issue
7
Pages
719–724
Identifiers
DOI: 10.1002/gps.2413
PMID: 19946863
Source
Medline
License
Unknown

Abstract

The population impact of new NICE criteria of excluding high MMSE scores is to exclude one in five individuals with AD and a further one in ten of those with a mixed disease. Changing the guidance has almost balanced the loss of treatment for the high MMSE group (13%) with the introduction of treatment for those scoring 10/11 (11%).

Statistics

Seen <100 times